Willem Marijt
- Naam
- Dr. W.A.F. Marijt
- Telefoon
- +31 71 526 2271
- w.a.f.marijt@umail.leidenuniv.nl
- Faculteit Geneeskunde
- Divisie 2
- Hematologie
- Hematologie algemeen
- Zouwen, B. van der; Koster, E.A.S.; Borne, P.A. von dem; Oosten, L.E.M.; Roza-Scholten, M.W.I.; Snijders, T.J.F.; Lammeren, D. van; Balen, P. van; Marijt, W.A.F.; Veelken, H.; Falkenburg, J.H.F.; Wreede, L.C. de & Halkes, C.J.M. (2023), Feasibility, safety, and efficacy of early prophylactic donor lymphocyte infusion after T cell-depleted allogeneic stem cell transplantation in acute leukemia patients, Annals of Hematology 102.
- Starreveld, D.E.J.; Daniels, L.A.; Kieffer, J.M.; Valdimarsdottir, H.B.; Geus, J. de; Lanfermeijer, M.; Someren, E.J.W. van; Habers, G.E.A.; Bosch, J.A.; Janus, C.P.M.; Spronsen, D.J. van; Weijer, R.J. de; Marijt, E.W.A.; Jongh, E. de; Zijlstra, J.M.; Bohmer, L.H.; Houmes, M.; Kersten, M.J.; Korse, C.M.; Rossum, H.H. van; Redd, W.H.; Lutgendorf, S.K.; Ancoli-Israel, S.; Leeuwen, F.E. van & Bleiker, E.M.A. (2021), Light therapy for cancer-related fatigue in (non-)Hodgkin lymphoma survivors, Cancers 13(19).
- Henes, J.; Oliveira, M.C.; Labopin, M.; Badoglio, M.; Scherer, H.U.; Papa, N. del; Daikeler, T.; Schmalzing, M.; Schroers, R.; Martin, T.; Pugnet, G.; Simoes, B.; Michonneau, D.; Marijt, E.W.A.; Lioure, B.; Bay, J.O.; Snowden, J.A.; Rovira, M.; Huynh, A.; Onida, F.; Kanz, L.; Marjanovic, Z.; Farge, D. & NISSC1 Members (2021), Autologous stem cell transplantation for progressive systemic sclerosis, Haematologica 106(2): 375-383.
- Spierings, J.; Rhenen, A. van; Welsing, P.M.W.; Marijnissen, A.C.A.; Langhe, E. de; Papa, N. del; Dierickx, D.; Gheorghe, K.R.; Henes, J.; Hesselstrand, R.; Kerre, T.; Ljungman, P.; Loosdrecht, A.A. van de; Marijt, E.W.A.F.; Mayer, M.; Schmalzing, M.; Schroers, R.; Smith, V.; Voll, R.E.; Vonk, M.C.; Voskuyl, A.E.; Vries-Bouwstra, J.K. de; Walker, U.A.; Wuttge, D.M. & Laar, J.M. van (2021), A randomised, open-label trial to assess the optimal treatment strategy in early diffuse cutaneous systemic sclerosis, BMJ Open 11(3).
- Chamuleau, M.E.D.; Burggraaff, C.N.; Nijland, M.; Bakunina, K.; Mous, R.; Lugtenburg, P.J.; Dierickx, D.; Imhoff, G.W. van; Vermaat, J.S.P.; Marijt, E.A.F.; Visser, O.; Mandigers, C.; Bilgin, Y.M.; Beeker, A.; Durian, M.F.; Rees, B.P. van; Bohmer, L.H.; Tick, L.W.; Boersma, R.S.; Snijders, T.J.F.; Schouten, H.C.; Koene, H.R.; Jongh, E. de; Hijmering, N.; Diepstra, A.; Berg, A. van de; Arens, A.I.J.; Huijbregts, J.; Hoekstra, O.; Zijlstra, J.M.; Jong, D. de & Kersten, M.J. (2020), Treatment of patients with MYC rearrangement positive large B-cell lymphoma with R-CHOP plus lenalidomide, Haematologica 105(12): 2805-2812.
- Hosnijeh, F.S.; Straten, L. van der; Kater, A.P.; Oers, M.H.J. van; Posthuma, W.F.M.; Chamuleau, M.E.D.; Bellido, M.; Doorduijn, J.K.; Gelder, M. van; Hoogendoorn, M.; Boer, F. de; Raa, G.D. te; Kerst, J.M.; Marijt, E.W.A.; Raymakers, R.A.P.; Koene, H.R.; Schaafsma, M.R.; Dobber, J.A.; Tonino, S.H.; Kersting, S.S.; Langerak, A.W. & Levin, M.D. (2020), Proteomic markers with prognostic impact on outcome of chronic lymphocytic leukemia patients under chemo-immunotherapy, Experimental Hematology 89: 55-+.
- Bijnen, S. van; Vries-Bouwstra, J. de; Ende, C.H. van den; Boonstra, M.; Kroft, L.; Geurts, B.; Snoeren, M.; Schouffoer, A.; Spierings, J.; Laar, J.M. van; Huizinga, T.W.J.; Voskuyl, A.; Marijt, E.; Velden, W. van der; Hoogen, F.H.J. van den & Vonk, M.C. (2020), Predictive factors for treatment-related mortality and major adverse events after autologous haematopoietic stem cell transplantation for systemic sclerosis: results of a long-term follow-up multicentre study, Annals of the Rheumatic Diseases 79(8): 1084-1089.
- Kater, A.P.; Oers, M.H.J. van; Norden, Y. van; Straten, L. van der; Driessen, J.; Posthuma, W.F.M.; Schipperus, M.; Chamuleau, M.E.D.; Nijland, M.; Doorduijn, J.K.; Gelder, M. van; Hoogendoorn, M.; Croon, F. de; Wittebol, S.; Kerst, J.M.; Marijt, E.W.A.; Raymakers, R.A.P.; Schaafsma, M.R.; Dobber, J.A.; Kersting, S.; Levin, M.D. & HOVON CLL Study Grp (2019), Feasibility and efficacy of addition of individualized-dose lenalidomide to chlorambucil and rituximab as first-line treatment in elderly and FCR-unfit patients with advanced chronic lymphocytic leukemia, Haematologica 104(1): 147-154.
- Lam, T.S.; Meent, M. van de; Marijt, E.W.A.; Falkenburg, J.H.F. & Jedema, I. (2018), Immune surveillance by autoreactive CD4-positive helper T cells is a common phenomenon in patients with acute myeloid leukemia, European Journal of Haematology 101(5): 665-675.
- Heiden, P. van der; Marijt, E.; Falkenburg, F. & Jedema, I. (2018), Control of Cytomegalovirus Viremia after Allogeneic Stem Cell Transplantation: A Review on CMV-Specific T Cell Reconstitution, Biology of Blood and Marrow Transplantation 24(9): 1776-1782.
- Heiden, P.L.J. van der; Egmond, H.M. van; Veld, S.A.J.; Meent, M. van de; Eefting, M.; Wreede, L.C. de; Halkes, C.J.M.; Falkenburg, J.H.F.; Marijt, W.A.F. & Jedema, I. (2018), CMV seronegative donors: Effect on clinical severity of CMV infection and reconstitution of CMV-specific immunity, Transplant Immunology 49: 54-58.
- Eefting, M.; Wreede, L.C. de; Borne, P.A. von dem; Halkes, C.J.M.; Kersting, S.; Marijt, E.W.A.; Putter, H.; Veelken, H.; Schetelig, J. & Falkenburg, J.H.F. (2017), Donor T-cell responses and disease progression patterns of multiple myeloma, Bone Marrow Transplantation 52(12): 1609-1615.
- Persoon, S.; Chinapaw, M.J.M.; Buffart, L.M.; Liu, R.D.K.; Wijermans, P.; Koene, H.R.; Minnema, M.C.; Lugtenburg, P.J.; Marijt, E.W.A.; Brug, J.; Nollet, F. & Kersten, M.J. (2017), Randomized controlled trial on the effects of a supervised high intensity exercise program in patients with a hematologic malignancy treated with autologous stem cell transplantation: Results from the EXIST study, PLoS ONE 12(7).
- Pont, M.J.; Lee, D.I. van der; Meijden, E. van der; Bergen, C.A.M. van; Kester, M.G.D.; Honders, M.W.; Vermaat, M.; Eefting, M.; Marijt, E.W.A.; Kielbasa, S.M.; Hoen, P.A.C. 't; Falkenburg, J.H.F. & Griffioen, M. (2016), Integrated Whole Genome and Transcriptome Analysis Identified a Therapeutic Minor Histocompatibility Antigen in a Splice Variant of ITGB2, Clinical Cancer Research 22(16): 4185-4196.
- Borne, P.A.V.; Wreede, L.C. de; Halkes, C.J.M.; Marijt, W.A.F.; Falkenburg, J.H.F. & Veelken, H. (2016), Effectivity of a strategy in elderly AML patients to reach allogeneic stem cell transplantation using intensive chemotherapy: Long-term survival is dependent on complete remission after first induction therapy, Leukemia Research 46: 45-50.
- Preijers, F.W.M.B.; Velden, V.H.J. van der; Preijers, T.; Brooimans, R.A.; Marijt, E.; Homburg, C.; Montfort, K. van; Gratama, J.W. & Sect Immunological Molecular Cell (2016), Fifteen Years of External Quality Assessment in Leukemia/Lymphoma Immunophenotyping in The Netherlands and Belgium: A Way Forward, Cytometry Part B: Clinical Cytometry 90(3): 267-278.
- Pont, M.J.; Honders, M.W.; Kremer, A.N.; Kooten, C. van; Out, C.; Hiemstra, P.S.; Boer, H.C. de; Jager, M.J.; Schmelzer, E.; Vries, R.G.; Hinai, A.S. al; Kroes, W.G.; Monajemi, R.; Goeman, J.J.; Bohringer, S.; Marijt, W.A.F.; Falkenburg, J.H.F. & Griffioen, M. (2016), Microarray Gene Expression Analysis to Evaluate Cell Type Specific Expression of Targets Relevant for Immunotherapy of Hematological Malignancies, PLoS ONE 11(5).
- Eefting, M.; Wreede, L.C. de; Halkes, C.J.M.; Borne, P.A. von dem; Kersting, S.; Marijt, E.W.A.; Veelken, H.; Putter, H.; Schetelig, J. & Falkenburg, J.H.F. (2016), Multi-state analysis illustrates treatment success after stem cell transplantation for acute myeloid leukemia followed by donor lymphocyte infusion, Haematologica 101(4): 506-514.
- Gooskens, J.; Marijt, W.A.F.; Essen, E.H.R. van; Rimmelzwaan, G.F. & Kroes, A.C.M. (2016), Host immunity dictates influenza A(H1N1)pdm09 infection outcome in hematology-oncology patients, Bone Marrow Transplantation 51(1): 138-141.
- Pont, M.J.; Honders, M.W.; Kremer, A.N.; Kooten, C. van; Out, C.; Hiemstra, P.S.; Boer, H.C. de; Jager, M.J.; Schmelzer, E.; Vries, R.G.; Hinai, A.S. al; Kroes, W.G.; Monajemi, R.; Goeman, J.J.; Bohringer, S.; Marijt, W.A.F.; Falkenburg, J.H.F. & Griffioen, M. (2016), Microarray gene expression analysis to evaluate cell type specific expression of targets relevant for immunotherapy of hematological malignancies., PLoS Medicine 11.
- Eefting, M.; Wreede, L. de; Borne, P.V.; Halkes, C.; Kersting, S.; Marijt, E.; Putter, H.; Veelken, H.; Schetelig, J. & Falkenburg, F. (2015), Donor T-cell responses modulate disease progression patterns of multiple myeloma after T-cell depleted allogeneic stem cell transplantation, Bone Marrow Transplantation 50: S15-S16.
- Halteren, A. van; Griendt, I. van der; Kemps-Mols, B.; Eikmans, M.; Marijt, E.; Netelenbos, T.; Griffioen, M.; Lankester, A. & Tol, M. van (2015), Passive transfer of male microchimeric cells from female donors to female HSCT patients: a case report, Bone Marrow Transplantation 50: S150-S151.
- Somers, J.A.E.; Braakman, E.; Holt, B. van der; Petersen, E.J.; Marijt, E.W.A.; Huisman, C.; Sintnicolaas, K.; Oudshoorn, M.; Groenendijk-Sijnke, M.E.; Brand, A. & Cornelissen, J.J. (2014), Rapid induction of single donor chimerism after double umbilical cord blood transplantation preceded by reduced intensity conditioning: results of the HOVON 106 phase II study, Haematologica 99(11): 1753-1761.
- Heiden, P.L.J. van der; Arbous, M.S.; Beers, W. van; Bergh, W.M. van den; Hess, C.; Kusadasi, N.; Marijt, W.A.F.; Muller, M.C.; Tuinman, P.R.; Vliet, M. van; Westerloo, D.J. van; Blijlevens, N. & HemIC Study Grp (2014), COMPARABLE SURVIVAL OF CRITICALLY ILL PATIENTS ADMITTED TO THE ICU FOLLOWING REDUCED INTENSITY AND MS ELOABLATIVE CONDITIONLNG ALLOGENEIC STEM CELL TRANSPLANTATION, Intensive Care Medicine 40: S179-S180.
- Aslanyan, M.G.; Kroeze, L.I.; Langemeijer, S.M.C.; Koorenhof-Scheele, T.N.; Massop, M.; Hoogen, P. van; Stevens-Linders, E.; Locht, L.T. van de; Tonnissen, E.; Heijden, A. van der; Silva-Coelho, P. da; Cilloni, D.; Saglio, G.; Marie, J.P.; Tang, R.P.; Labar, B.; Amadori, S.; Muus, P.; Willemze, R.; Marijt, E.W.A.; Witte, T. de; Reijden, B.A. van der; Suciu, S. & Jansen, J.H. (2014), Clinical and biological impact of TET2 mutations and expression in younger adult AML patients treated within the EORTC/GIMEMA AML-12 clinical trial, Annals of Hematology 93(8): 1401-1412.
- Laar, J.M. van; Farge, D.; Sont, J.K.; Naraghi, K.; Marjanovic, Z.; Larghero, J.; Schuerwegh, A.J.; Marijt, E.W.A.; Vonk, M.C.; Schattenberg, A.V.; Matucci-Cerinic, M.; Voskuyl, A.E.; Loosdrecht, A.A. van de; Daikeler, T.; Kotter, I.; Schmalzing, M.; Martin, T.; Lioure, B.; Weiner, S.M.; Kreuter, A.; Deligny, C.; Durand, J.M.; Emery, P.; Machold, K.R.; Sarrot-Reynauld, F.; Warnatz, K.; Adoue, D.F.P.; Constans, J.; Tony, H.P.; Papa, N. del; Fassas, A.; Himsel, A.; Launay, D.; Monaco, A. lo; Philippe, P.; Quere, I.; Rich, E.; Westhovens, R.; Griffiths, B.; Saccardi, R.; Hoogen, F.H. van den; Fibbe, W.E.; Socie, G.; Gratwohl, A.; Tyndall, A. & EBMT EULAR Scleroderma Study Grp (2014), Autologous Hematopoietic Stem Cell Transplantation vs Intravenous Pulse Cyclophosphamide in Diffuse Cutaneous Systemic Sclerosis A Randomized Clinical Trial, Journal of the American Medical Association 311(24): 2490-2498.
- Eefting, M.; Borne, P.A. von dem; Wreede, L.C. de; Halkes, C.J.M.; Kersting, S.; Marijt, E.W.A.; Veelken, H. & Falkenburg, J.H.F. (2014), Intentional donor lymphocyte-induced limited acute graft-versus-host disease is essential for long-term survival of relapsed acute myeloid leukemia after allogeneic stem cell transplantation, Haematologica 99(4): 751-758.
- Eefting, M.; Halkes, C.J.M.; Wreede, L.C. de; Pelt, C.M. van; Kersting, S.; Marijt, E.W.A.; Borne, P.A. von dem; Willemze, R.; Veelken, H. & Falkenburg, J.H.F. (2014), Myeloablative T cell-depleted alloSCT with early sequential prophylactic donor lymphocyte infusion is an efficient and safe post-remission treatment for adult ALL, Bone Marrow Transplantation 49(2): 287-291.
- Bauer, M.P.; Marijt, E.W.A. & Kroon, F.P. (2014), cART Reverses Hyposplenism in HIV-1 Infection, Journal of Acquired Immune Deficiency Syndromes 65(2): E88-E90.
- Willemze, R.; Suciu, S.; Meloni, G.; Labar, B.; Marie, J.P.; Halkes, C.J.M.; Muus, P.; Mistrik, M.; Amadori, S.; Specchia, G.; Fabbiano, F.; Nobile, F.; Sborgia, M.; Camera, A.; Selleslag, D.L.D.; Lefrere, F.; Magro, D.; Sica, S.; Cantore, N.; Beksac, M.; Berneman, Z.; Thomas, X.; Melillo, L.; Guimaraes, J.E.; Leoni, P.; Luppi, M.; Mitra, M.E.; Bron, D.; Fillet, G.; Marijt, E.W.A.; Venditti, A.; Hagemeijer, A.; Mancini, M.; Jansen, J.; Cilloni, D.; Meert, L.; Fazi, P.; Vignetti, M.; Trisolini, S.M.; Mandelli, F. & Witte, T. de (2014), High-Dose Cytarabine in Induction Treatment Improves the Outcome of Adult Patients Younger Than Age 46 Years With Acute Myeloid Leukemia: Results of the EORTC-GIMEMA AML-12 Trial, Journal of Clinical Oncology 32(3): 219-+.
- Brink, M.H. ten; Swen, J.J.; Bohringer, S.; Wessels, J.A.M.; Straaten, T. van der; Marijt, E.W.A.; Borne, P.A. von dem; Zwaveling, J. & Guchelaar, H.J. (2013), Exploratory analysis of 1936 SNPs in ADME genes for association with busulfan clearance in adult hematopoietic stem cell recipients, Pharmacogenetics and Genomics 23(12): 675-683.
- Daniels, L.A.; Krol, A.D.G.; Schaapveld, M.; Putter, H.; Jansen, P.M.; Marijt, E.W.A.; Leeuwen, F.E. van & Creutzberg, C.L. (2013), Long-term risk of secondary skin cancers after radiation therapy for Hodgkin's lymphoma, Radiotherapy and Oncology 109(1): 140-145.
- Stevanovic, S.; Bergen, C.A.M. van; Luxemburg-Heijs, S.A.P. van; Zouwen, B. van der; Jordanova, E.S.; Kruisselbrink, A.B.; Meent, M.V. de; Harskamp, J.C.; Claas, F.H.J.; Marijt, E.W.A.; Zwaginga, J.J.; Halkes, C.J.M.; Jedema, I.; Griffioen, M. & Falkenburg, J.H.F. (2013), HLA class II upregulation during viral infection leads to HLA-DP-directed graft-versus-host disease after CD4+donor lymphocyte infusion, Blood 122(11): 1963-1973.
- Somers, J.A.E.; Holt, B. van der; Sintnicolaas, K.; Oudshoorn, M.; Braakman, E.; Petersen, E.J.; Marijt, W.A.F.; Huisman, C.; Groenendijk-Sijnke, M.E.; Brand, A. & Cornelissen, J.J. (2013), HOVON 106: a phase II study to assess engraftment and engraftment kinetics after double cord blood transplantation preceded by a reduced-intensity conditioning regimen, Bone Marrow Transplantation 48: S64-S65.
- Eefting, M.; Borne, P.V.; Wreede, L. de; Halkes, C.; Kersting, S.; Marijt, E.; Veelken, H. & Falkenburg, F. (2013), Induction of limited acute GvHD by donor lymphocyte infusion early after cytoreduction is essential for long-term survival of patients with relapsed acute myeloid leukaemia after allogeneic stem cell transplantation, Bone Marrow Transplantation 48: S250-S250.
- Eefting, M.; Halkes, C.; Wreede, L. de; Pelt, M. van; Kersting, S.; Marijt, E.; Borne, P. von dem; Willemze, R.; Veelken, H. & Falkenburg, F. (2013), Myeloablative T-cell depleted allogeneic stem cell transplantation with early sequential prophylactic donor lymphocyte infusion for adult acute lymphoblastic leukaemia in first complete remission, Bone Marrow Transplantation 48: S395-S395.
- Balen, P. van; Bergen, A.M. van; Jedema, I.; Luxemburg-Heijs, S.A.P. van; Harskamp, J.C.; Egmond, H.M. van; Veld, S.A.J.; Griffioen, M.; Marijt, W.A.F.; Halkes, C.J.M. & Falkenburg, J.H.F. (2013), Purified CD4 T-cell infusion can result in graft-versus-leukaemia without GVHD by recognition of broadly expressed minor histocompatibility antigens restricted by HLA class-II, Bone Marrow Transplantation 48: S12-S13.
- Beek, M.T. van der; Vermont, C.L.; Bredius, R.G.M.; Marijt, E.W.A.; Blij-de Brouwer, C.S. van der; Kroes, A.C.M.; Claas, E.C.J. & Vossen, A.C.T.M. (2013), Persistence and Antiviral Resistance of Varicella Zoster Virus in Hematological Patients.
- Rutten, C.E.; Luxemburg-Heijs, S.A.P. van; Halkes, C.J.M.; Bergen, C.A.M. van; Marijt, E.W.A.; Oudshoorn, M.; Griffioen, M. & Falkenburg, J.H.F. (2013), Patient HLA-DP-Specific CD4(+) T Cells from HLA-DPB1-Mismatched Donor Lymphocyte Infusion Can Induce Graft-versus-Leukemia Reactivity in the Presence or Absence of Graft-versus-Host Disease, Biology of Blood and Marrow Transplantation 19(1): 40-48.
- Beek, M.T. van der; Marijt, E.W.A.F.; Vossen, A.C.T.M.; Blij-de Brouwer, C.S. van der; Wolterbeek, R.; Halkes, C.J.M.; Claas, E.C.J. & Kroes, A.C.M. (2012), Failure of pre-emptive treatment of cytomegalovirus infections and antiviral resistance in stem cell transplant recipients, Antiviral Therapy 17(1): 45-51.
- Beek, M.T. van der; Marijt, E.W.A.F.; Vossen, A.C.T.M.; Blij-de Brouwer, C.S. van der; Wolterbeek, R.; Halkes, C.J.M.; Claas, E.C.J. & Kroes, A.C.M. (2012), Failure of pre-emptive treatment of cytomegalovirus infections and antiviral resistance in stem cell transplant recipients., Antiviral Therapy 17(1): 45-51.
- Stijnis, C.; Kroes, W.G.M.; Balkassmi, S.; Marijt, E.W.A.; Rossum, A.P. van; Bakker, E. & Vlasveld, L.T. (2012), No Evidence for JAK2(V617F) Mutation in Monoclonal B Cells in 2 Patients with Polycythaemia Vera and Concurrent Monoclonal B Cell Disorder, Acta Haematologica 128(3): 183-186.
- Borne, P.A.V.; Halkes, C.J.M.; Marijt, E.W.A.; Kersting, S.; Falkenburg, J.H.F. & Veelken, J.H. (2012), Effectiveness of a Strategy to Proceed to Allogeneic Stem Cell Transplantation in All Elderly AML Patients Treated with Intensive Chemotherapy: Only Patients in Complete Remission After First Induction Show Long Term Survival., Blood 120(21).
- Meij, P.; Jedema, I.; Zandvliet, M.L.; Heiden, P.L.J. van der; Meent, M. van de; Egmond, H.M.E. van; Liempt, E. van; Hoogstraten, C.; Kruithof, S.; Veld, S.; Marijt, E.W.A.; Borne, P.A. von dem; Lankester, A.C.; Halkes, C.J.M. & Falkenburg, J.H.F. (2012), Effective Treatment of Refractory CMV Reactivation After Allogeneic Stem Cell Transplantation With In Vitro-generated CMV pp65-specific CD8(+) T-cell Lines, Journal of Immunotherapy 35(8): 621-628.
- Meij, P.; Jedema, I.; Hoorn, M.A.W.G. van der; Bongaerts, R.; Cox, L.; Wafelman, A.R.; Marijt, E.W.A.; Willemze, R. & Falkenburg, J.H.F. (2012), Generation and administration of HA-1-specific T-cell lines for the treatment of patients with relapsed leukemia after allogeneic stem cell transplantation: a pilot study, Haematologica 97(8): 1205-1208.
- Halkes, C.; Falkenburg, J.H.F.; Egmond, E. van; Meent, M. van; Borne, P. von dem; Marijt, W.A.F.; Veelken, J.H. & Jedema, I. (2012), Low incidence of viral complications after in vivo and in vitro T-cell depletion using low dose alemtuzumab is due to early post transplant outgrowth of protective virus specific CD4 and CD8 memory T-cells by various escape mechanisms, Bone Marrow Transplantation 47: S31-S31.
- Halkes, C.; Falkenburg, J.; Egmond, E. van; Wolbers, J.O.; Starrenburg, I.; Borne, P. von dem; Marijt, W.A.F.; Veelken, J.H. & Jedema, I. (2012), Rabbit-derived ATG but not horse-derived ATG in the conditioning induces a post transplant in vivo imbalance between B and T cell recovery resulting in high risk of EBV-associated PTLD, Bone Marrow Transplantation 47: S143-S143.
- Amir, A.L.; Hagedoorn, R.S.; Luxemburg-Heijs, S.A.P. van; Marijt, E.W.A.; Kruisselbrink, A.B.; Falkenburg, J.H.F. & Heemskerk, M.H.M. (2012), Identification of a Coordinated CD8 and CD4 T Cell Response Directed Against Mismatched HLA Class I Causing Severe Acute Graft-versus-Host Disease, Biology of Blood and Marrow Transplantation 18(2): 210-219.
- Preijers, F.; Velden, V. van der; Marijt, E.; Gratama, J.W.; Brooimans, R. & SKML (2011), THE SIHON (SKML) APPROACH OF EXTERNAL QUALITY ASSESSMENT IN LEUKEMIA/LYMPHOMA IMMUNOPHENOTYPING (IFT): 25 YEARS EXPERIENCE, Cytometry Part B: Clinical Cytometry 80B(6): 398-399.
- Somers, J.A.E.; Brand, A.; Holt, B. van der; Hensbergen, Y. van; Sintnicolaas, K.; Oudshoorn, M.; Mulder, A.; Braakman, E.; Huisman, C.; Janssen, J.J.W.M.; Marijt, E.W.A.F.; Petersen, E.J.; Groenendijk-Sijnke, M. & Cornelissen, J.J. (2011), Double Umbilical Cord Blood Transplantation Preceded by a Reduced-Intensity Conditioning Regimen: Rapid Induction of Single Donor Chimerism and Highly Predictive Value of Early CD4+ T Cell and NK Cell Predominance, Blood 118(21): 1303-1304.
- Halkes, C.J.M.; Falkenburg, J.H.F.; Egmond, H.M. van; Wolbers, J.O.; Starrenburg, C.W.J.; Balen, P. van; Meent, M. van de; Borne, P.A. von dem; Marijt, W.A.F.; Veelken, J.H. & Jedema, I. (2011), In Vivo T Cell Depletion Using Rabbit Derived ATG Leads to An Increased EBV-PTLD Risk Due to An Induced Imbalance Between B and T Cell Recovery Which Is Not Seen After Horse Derived ATG or Alemtuzumab, Blood 118(21): 864-864.
- Eefting, M.; Halkes, C.J.M.; Kersting, S.; Marijt, W.A.F.; Borne, P.A. von dem; Veelken, J.H. & Falkenburg, J.H.F. (2011), Long-Term Disease-Free Survival of Patients with AML Relapse After T-Cell-Depleted Allogeneic Stem Cell Transplantation by Re-Induction Therapy and Subsequent Interferon-Boosted Donor Lymphocyte Infusion, Blood 118(21): 1321-1321.
- Harskamp, J.C.; Nahon, J.E.; Siegel, A.M.; Vos, H.L.; Deutz-Terlouw, P.P.; Veelken, J.H.; Falkenburg, J.H.F. & Marijt, E.W.A. (2011), Quantitative Monitoring of NPM1A Mutations Can Be Used to Guide Immunotherapeutic Interventions After Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia, Blood 118(21): 1320-1320.
- Posthuma, C.C.; Beek, M.T. van der; Blij-de Brouwer, C.S. van der; Heiden, P.L.J. van der; Marijt, E.W.A.; Spaan, W.J.M.; Claas, E.C.J.; Nederstigt, C.; Vossen, A.C.T.M.; Snijder, E.J. & Kroes, A.C.M. (2011), Mass spectrometry-based comparative sequencing to detect ganciclovir resistance in the UL97 gene of human cytomegalovirus., Journal of Clinical Virology 51(1): 25-30.
- Noordermeer, S.M.; Tonnissen, E.; Vissers, I.; Heijden, A. van der; Locht, L.T. van de; Deutz-Terlouw, P.P.; Marijt, E.W.A.; Jansen, J.H. & Reijden, B.A. van der (2011), Rapid identification of IDH1 and IDH2 mutations in acute myeloid leukaemia using high resolution melting curve analysis, British Journal of Haematology 152(4): 493-496.
- Silva FP, Almeida I, Morolli B, Brouwer-Mandema G, Wessels H, Vossen R, Vrieling H, Marijt EW, Valk PJ, Kluin-Nelemans HC, Sperr WR, Ludwig WD & Giphart-Gassler M (2009), Genome wide molecular analysis of minimally differentiated acute myeloid leukemia.
- Silva FPG, Almeida I, Morolli B, Brouwer-Mandema G, Wessels H, Vossen R, Vrieling H, Marijt EWA, Valk PJM, Kluin-Nelemans HC, Sperr WR, Ludwig WD & Giphart-Gassler M (2009), Genome wide molecular analysis of minimally differentiated acute myeloid leukemia, Haematologica 94(11): 1546-1554.
- Aslanyan MG, Langemeijer SMC, Cilloni D, Saglio G, Marie JP, Tang R, Labar B, Zadro R, Batinic D, Amadori S, Lo Coco F, Scheele T, Kroeze L, Massop M, van Hoogen P, Stevens E, Muus P, Suciu S, Baila L, Marijt EWA, Willemze R, de Witte T, van der Reijden B & Jansen JH (2009), Incidence and Clinical Impact of TET2 Mutations in Acute Myeloid Leukemia Patients Treated within the EORTC/GIMEMA AML-12/06991 AML Trial., Blood 114(22): 1023-1024.
- Bauer MP, van Burgel ND, Marijt WAE, van Dissel JT & von dem Borne PA (2009), Fever, Shock, and Pancytopenia in a Patient Treated with Alemtuzumab, Clinical Infectious Diseases 49(10): 1540+.
- van der Heiden PLJ, de Boer R, van der Steen DM, Kester MGD, van der Hoorn MWAG, Haarman WME, Barnby-Porritt HE, Fry JW, Napper CE, Marijt EWA, Willemze R, Falkenburg JHF & Heemskerk MHM (2009), Identification of Varicella-Zoster Virus-Specific CD8 T Cells in Patients after T-Cell-Depleted Allogeneic Stem Cell Transplantation, Journal of Virology 83(14): 7361-7364.
- von dem Borne PA, Starrenburg CW, Halkes SJ, Marijt WA, Fibbe WE, Falkenburg JH & Willemze R (2009), Reduced-intensity conditioning allogeneic stem cell transplantation with donor T-cell depletion using alemtuzumab added to the graft ('Campath in the bag')., Current Opinion in Oncology 21 Suppl 1: S27-9.
- Gelinck LBS, van den Bemt BJF, Marijt WAF, van der Bijl AE, Visser LG, Cats HA, Rimmelzwaan GF & Kroon FP (2009), Intradermal influenza vaccination in immunocompromized patients is immunogenic and feasible, Vaccine 27(18): 2469-2474.
- Nijimeijer BA, Szuhai K, Goselink HM, van Schie MLJ, van der Burg M, de Jong D, Marijt EW, Ottrnann OG, Willemze R & Falkenburg JHF (2009), Long-term culture of primary human lymphoblastic leukemia cells in the absence of serum or hematopoietic growth factors, Experimental Hematology 37(3): 376-385.
- Borne PAVD, Starrenburg CWJI, Beaumont MF, Halkes SJM, Marijt EWA, Falkenburg JHF & Willemze R (2008), The Effect of Donor Lymphocyte Infusion Dose on the Occurrence of Severe Life-Threatening Acute Graft-Versus-Host Disease Early after Reduced Intensity Conditioning T Cell Depleted Stem Cell Transplantation., Blood 112(11): 773-773.
- Marijt WA, von dem Borne A, Barge MY, Deutz-Terlouw P, Beaumont M, Starrenburg CWJ, Fibbe E, Willemze R & Falkenburg JHF (2008), DONOR LYMPHOCYTE INFUSION FOR MIXED CHIMERISM AT 7 MONTHS AFTER T CELL DEPLETED ALLOGENEIC STEM CELL TRANSPLANTATION REDUCES RELAPSE RISK, Haematologica 93: 241-241.
- Rutten CE, van Luxemburg-Heijs SAP, Griffioen M, Marijt WAE, Jedema I, Heemskerk MHM, Posthuma FM, Willemze R & Falkenburg JH (2008), HLA-DP AS SPECIFIC TARGET FOR GRAFT VERSUS LEUKEMIA REACTIVITY IN HLA-CLASS II EXPRESSING HEMATOLOGICAL MALIGNANCIES, Haematologica 93: 351-352.
- Amir A, Hagedoorn RS, Marijt EAF, Willenize R, Falkenburg JHF & Heewskerk MHM (2008), LEUKEMIC BLASTS ACTING AS HOST ANTIGEN PRESENTING CELLS TRIGGER A COMBINED CD4 AND CD8 ALLO-IMMUNE RESPONSE DIRECTED AGAINST MISMATCHED HLA CLASS I, Biology of Blood and Marrow Transplantation 14(2): 136-136.